CAR T-cell Therapy Improves Survival in Relapsed or Refractory Lymphoma - News Center

"Historically, patients with MZL who have had one to two treatments in the past struggle with maintaining a long-term response with subsequent therapies. We expect diminishing returns with each treatment. This is a population that has been routinely marginalized and not well studied in the setting of a clinical trial; therefore, innovations and new treatments in this group have been slow to develop."

"Liso-cel works by targeting a protein on the surface of the lymphoma cell, which then activates re-engineered T-cells to target and kill lymphoma cells. Patients were enrolled at 30 sites across the U.S., Canada, Europe and Japan, and received a single dose of liso-cel two to seven days following lymphodepleting chemotherapy."

Marginal zone lymphoma is a rare, slow-growing non-Hodgkin lymphoma originating from B-cells that spreads to lymphoid tissues, lymph nodes, stomach, and bone marrow. Many patients remain asymptomatic for years, but some develop aggressive disease and relapse despite chemotherapy, immunotherapy, or targeted treatments. Treatment options for relapsed or refractory cases are limited. A clinical trial evaluated lisocabtagene maraleucel, a CAR T-cell therapy targeting lymphoma cell surface proteins, in 67 patients with relapsed or refractory marginal zone lymphoma who had received at least two prior therapies. Patients received a single liso-cel dose following lymphodepleting chemotherapy across 30 international sites. Results demonstrated high response rates with sustained disease control at two years.

Read at News Center